Tirzepatide reduced the risk of death from cardiovascular causes or worsening heart failure compared to placebo in patients with heart failure with preserved ejection fraction and obesity.
Does tirzepatide reduce the risk of cardiovascular death or worsening heart failure in patients with heart failure with preserved ejection fraction and obesity?
Tirzepatide reduces the risk of cardiovascular death or worsening heart failure and improves health status in patients with HFpEF and obesity.
Absolute Event Rate: 0% vs 0%
Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with preserved ejection fraction and obesity. (Funded by Eli Lilly; SUMMIT ClinicalTrials.gov number, NCT04847557.).
“In my mind, this really is a practice-changing trial and cements incretin-based therapies as one of the cornerstones of obesity-HFpEF treatment.”
Multiple 2026 post-hoc and real-world analyses (SURPASS-CVOT, PCI/TAVR cohorts) amplifying original trial; >1,000 social mentions in past 14 days, widespread news coverage linking to reduced CV risk post-procedure, high clinical buzz on GLP-1/GIP use in cardiology.
Packer et al. (Sat,) reported a other. Tirzepatide reduced the risk of death from cardiovascular causes or worsening heart failure compared to placebo in patients with heart failure with preserved ejection fraction and obesity.